Cambridge, MA, Jul 5, 2023 – (ACN Newswire) – Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided an update on regulatory submissions for mRNA-1345, a vaccine for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults aged 60 years or older.The Company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA…
Read More
About The Author
